[Federal Register: June 30, 2004 (Volume 69, Number 125)]
[Notices]
[Page 39487-39488]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr30jn04-85]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing: SARS-
Related Technologies
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of Federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive
[[Page 39488]]
Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/
496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement
will be required to receive copies of the patent applications.
SARS Coronavirus MVA Vaccines and Therapy
Bernard Moss (NIAID).
U.S. Provisional Application No. 60/558,995 filed 05 Apr 2004 (DHHS
Reference No. E-165-2004/0-US-01).
Licensing Contact: Michael Shmilovich; 301/435-5019;
shmilovm@mail.nih.gov.
Intranasal or intramuscular inoculations of BALB/c mice with
modified vaccinia Ankara (MVA) vector encoding SARS-CoV Spike protein
produced serum antibodies that recognized SARS S in ELISA and elicited
protective immunity as shown by reduced titers of SARS-CoV in the upper
and lower respiratory tracts of mice following challenge. Passive
transfer of serum from mice immunized with MVA/S to naive mice also
reduced the replication of SARS-CoV in the respiratory tract following
challenge, demonstrating the role of antibody to S in protection.
Enhanced Sensitivity ELISA for SARS Diagnostic
Gary J. Nabel et al. (NIAID).
U.S. Provisional Application No. 60/503,508 filed 15 Sep 2003 (DHHS
Reference No. E-334-2003/0-US-01).
U.S. Provisional Application No. 60/550,317 filed 08 Mar 2004 (DHHS
Reference No. E-334-2003/1-US-01).
Licensing Contact: Michael Shmilovich; 301/435-5019;
shmilovm@mail.nih.gov.
Reagents and protocols for extremely sensitive ELISA for use as a
SARS diagnostic are described. The ELISA uses recombinant-expressed
nucleoprotein (N) or spike (S) glycoprotein from the SARS coronavirus
as capture antigens. As little as five (5) days after onset, detection
of antibody response is possible. The ELISA described herein is more
sensitive than existing technology because of the N and S proteins;
existing ELISAs use formalin-inactivated whole virus or peptides.
E-334-2003/1-US-01 also describes DNA Vaccines (CMV/R-SARS-S
plasmid) including a nucleic acid encoding the peptide of SARS Spike
glycoprotein, the RSV enhancer, the mouse ubiquitin enhancer (mUBB),
and the CMV enhancer (Xu et al. 1998 Nature Med. 4: 37-42). Optionally
the HTLV-1 R region (Takebe et al. 1988 Mol Cell Biol 8: 466-472) is
also included.
Interferon-Alpha SARS Treatment
Kathryn C. Zoon, Renqui Hu, Joseph B. Bekisz (NCI).
U.S. Provisional Application filed 30 Apr 2004 (DHHS Reference No.
E-278-2003/0-US-01).
Licensing Contact: Michael Shmilovich; 301/435-5019;
shmilovm@mail.nih.gov.
The Public Health Service seeks a licensee to commercialize protein
engineered human interferon alphas for treating and/or preventing a
SARS-associated coronaviral infection in humans and other relevant
mammalian species.
Soluble SARS Coronavirus Spike Protein (S Protein)
Dimiter S. Dimitrov, Xiadong Xiao (NCI).
U.S. Provisional Application No. 60/489,166 filed 21 Jul 2003 (DHHS
Reference No. E-228-2003/0-US-01).
Licensing Contact: Michael Shmilovich; 301/435-5019;
shmilovm@mail.nih.gov.
The SARS coronavirus is etiologically linked to severe acute
respiratory syndrome. Soluble forms of the SARS coronavirus spike
protein have been cloned, expressed and characterized, and are
available for licensing for use as research reagents, in the
development of vaccines and inhibitors of the viral infection, for
selection of monoclonal antibodies, and development of kits containing
antibodies that bind to the spike protein. The filed patent application
additionally claims the associated spike protein polypeptides, peptide
fragments, and conserved variants thereof; nucleic acid segments and
constructs that encode the spike protein, polypeptides and peptide
fragments of the spike protein, and conserved variants thereof and
coupled proteins that include the spike protein or a portion thereof
and peptidomimetics.
Dated: June 20, 2004.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 04-14750 Filed 6-29-04; 8:45 am]
BILLING CODE 4140-01-P